Loading provider…
Loading provider…
Urology Physician in Gainesville, FL
NPI: 1194121053Primary Practice Location
UF HEALTH SHANDS HOSPITAL
4101 Nw 89th Blvd, Gainesville, FL
Primary Employer
UF Health Physicians
ufhealth.org
HQ Phone
Get MD Padraic's Phone Numberphone_androidMobile
Get MD Padraic's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
FL State Medical License
2018 - 2027

American Board of Urology
Urology

FRCSC-Fellow Royal College of Surgeons of Canada
Urology
New York Presbyterian Hospital (Columbia and Cornell Campus)
Fellowship • Urologic Surgical Oncology
2014 - 2016
University of Toronto (Canada)
2013 - 2014
University of Toronto
Residency • 2009 - 2014
2009 - 2014
Saba University School of Medicine
Medical School
Until 2009
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 126 | 159 |
| 2 | 52000Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | 99 | 139 |
| 3 | 81003Automated urinalysis test | 64 | 108 |
| 4 | 51720Instillation of anti-cancer drug into bladder | 38 | 85 |
| 5 | J9030Bcg live intravesical instillation, 1 mg | 37 | 1,848 |
Minimally invasive vs open nephrectomy in the modern era: does approach matter?
Authors: Bilal Chughtai, Joseph Del Pizzo, Douglas Scherr, Jim Hu
Journal: World J Urol
Publication Date: 2017-05-05
Vasectomy and Risk of Prostate Cancer in a Screening Trial
Authors: Christopher Barbieri, Douglas Scherr, Jim Hu, Joshua Halpern, Ron Golan
Journal: Cancer Epidemiol Biomarkers Prev
Publication Date: 2017-08-22
Lead Sponsor: ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Docetaxel, DRUG: Gemcitabine, DRUG: Bacillus Calmette Guerin
Lead Sponsor: Janssen Research & Development, LLC
Intervention / Treatment: BIOLOGICAL: Cetrelimab, DRUG: TAR-200
Lead Sponsor: Merck Sharp & Dohme LLC
Collaborators: Astellas Pharma Inc, Seagen Inc.
Intervention / Treatment: BIOLOGICAL: Pembrolizumab, DRUG: Cisplatin, DRUG: Gemcitabine, BIOLOGICAL: Enfortumab vedotin (EV), PROCEDURE: RC + PLND